Gan & Lee Pharmaceuticals Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100003ZH1
CNY
61.72
3.13 (5.34%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Jun'24
Mar'24
Net Sales
980.24
1,081.93
975.80
791.49
930.11
746.38
560.33
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
980.24
1,081.93
975.80
791.49
930.11
746.38
560.33
Raw Material Cost
234.87
288.58
255.52
243.68
234.55
223.29
178.69
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Selling and Distribution Expenses
385.37
377.78
382.26
384.82
389.10
306.75
254.80
Other Expenses
14.33
12.33
11.96
12.61
12.55
12.25
12.23
Total Expenditure (Excl Depreciation)
763.58
789.64
757.43
754.64
749.16
652.54
555.76
Operating Profit (PBDIT) excl Other Income
216.70000000000002
292.3
218.4
36.9
181
93.80000000000001
4.6000000000000005
Other Income
20.15
29.94
95.03
56.89
35.83
64.85
29.70
Operating Profit (PBDIT)
227.59
384.42
385.16
145.12
276.03
221.23
90.62
Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Exceptional Items
7.10
17.97
46.99
-11.29
13.78
68.63
85.50
Gross Profit (PBDT)
745.37
793.35
720.28
547.81
695.56
523.09
381.64
Depreciation
0.00
71.76
71.76
67.05
67.05
62.56
62.56
Profit Before Tax
234.69
330.63
360.39
66.78
222.75
227.29
113.56
Tax
20.03
38.87
48.47
-40.62
14.39
24.39
17.56
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
214.66
291.76
311.92
107.40
208.36
202.90
96.00
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
214.66
291.76
311.92
107.40
208.36
202.90
96.00
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
-0.00
-0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
214.66
291.76
311.92
107.40
208.36
202.90
96.00
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
11,282.39
10,965.23
11,312.12
11,054.47
11,206.86
10,977.09
10,842.59
Earnings per share (EPS)
0.37
0.49
0.53
0.18
0.35
0.34
0.16
Diluted Earnings per share
0.37
0.49
0.53
0.18
0.35
0.34
0.16
Operating Profit Margin (Excl OI)
21.16%
26.13%
22.38%
2.68%
18.62%
12.57%
-0.29%
Gross Profit Margin
23.94%
37.19%
44.29%
16.91%
31.16%
38.83%
31.43%
PAT Margin
21.9%
26.97%
31.97%
13.57%
22.4%
27.18%
17.13%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - QoQ
stock-summary

Net Sales

QoQ Growth in quarter ended Sep 2025 is -9.40% vs 10.87% in Jun 2025

stock-summary

Consolidate Net Profit

QoQ Growth in quarter ended Sep 2025 is -26.42% vs -6.44% in Jun 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Sep 2025 is -41.50% vs 22.20% in Jun 2025

stock-summary

Interest

No Interest in the last few periods

stock-summary

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Sep 2025 has fallen from Jun 2025

Compare Quarterly Results Of Gan & Lee Pharmaceuticals Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(CNY)
Change(%)
Net Sales
980.24
0
980.24
Other Operating Income
0.00
0.00
0.00
Total Operating income
980.24
0
980.24
Raw Material Cost
234.87
0
234.87
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
0.00
0
0.00
Selling and Distribution Expenses
385.37
0
385.37
Other Expenses
14.33
0.00
14.33
Total Expenditure (Excl Depreciation)
763.58
0
763.58
Operating Profit (PBDIT) excl Other Income
216.66
0.00
216.66
Other Income
20.15
0
20.15
Operating Profit (PBDIT)
227.59
0
227.59
Interest
0.00
0
0.00
Exceptional Items
7.10
0
7.10
Gross Profit (PBDT)
745.37
0
745.37
Depreciation
0.00
0
0.00
Profit Before Tax
234.69
0
234.69
Tax
20.03
0
20.03
Provisions and contingencies
0
0
0.00
Profit After Tax
214.66
0
214.66
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
214.66
0
214.66
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
0
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
214.66
0
214.66
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
11,282.39
0
11,282.39
Earnings per share (EPS)
0.37
0
0.37
Diluted Earnings per share
0.37
0
0.37
Operating Profit Margin (Excl OI)
21.16%
0%
0.00
21.16%
Gross Profit Margin
23.94%
0%
0.00
23.94%
PAT Margin
21.90%
0%
0.00
21.90%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 98.02 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is -9.40% vs 10.87% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is 5.39% vs 37.61% in Sep 2024

Quarterly - Consolidate Net Profit
Consolidate Net Profit 21.47 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is -26.42% vs -6.44% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is 3.02% vs 57.52% in Sep 2024

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 20.74 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is -41.50% vs 22.20% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is -13.66% vs 31.98% in Sep 2024

Quarterly - Interest
Markets Mojo
No Interest in the last few periods
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 21.16%
in Sep 2025

Figures in %
stock-summary

QoQ Growth in quarter ended Sep 2025 has fallen from Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 has improved from Sep 2024